162 related articles for article (PubMed ID: 26449354)
1. Bone mineral density changes among women initiating blood pressure lowering drugs: a SWAN cohort study.
Solomon DH; Ruppert K; Zhao Z; Lian YJ; Kuo IH; Greendale GA; Finkelstein JS
Osteoporos Int; 2016 Mar; 27(3):1181-1189. PubMed ID: 26449354
[TBL] [Abstract][Full Text] [Related]
2. Rates of bone loss among women initiating antidepressant medication use in midlife.
Diem SJ; Ruppert K; Cauley JA; Lian Y; Bromberger JT; Finkelstein JS; Greendale GA; Solomon DH
J Clin Endocrinol Metab; 2013 Nov; 98(11):4355-63. PubMed ID: 24001746
[TBL] [Abstract][Full Text] [Related]
3. The effect of insulin on bone mineral density among women with type 2 diabetes: a SWAN Pharmacoepidemiology study.
Ruppert K; Cauley J; Lian Y; Zgibor JC; Derby C; Solomon DH
Osteoporos Int; 2018 Feb; 29(2):347-354. PubMed ID: 29075805
[TBL] [Abstract][Full Text] [Related]
4. Bone mineral density changes among women initiating proton pump inhibitors or H2 receptor antagonists: a SWAN cohort study.
Solomon DH; Diem SJ; Ruppert K; Lian YJ; Liu CC; Wohlfart A; Greendale GA; Finkelstein JS
J Bone Miner Res; 2015 Feb; 30(2):232-9. PubMed ID: 25156141
[TBL] [Abstract][Full Text] [Related]
5. Which is the preferred site for bone mineral density monitoring as an indicator of treatment-related anti-fracture effect in routine clinical practice? A registry-based cohort study.
Leslie WD; Martineau P; Bryanton M; Lix LM
Osteoporos Int; 2019 Jul; 30(7):1445-1453. PubMed ID: 31016351
[TBL] [Abstract][Full Text] [Related]
6. Long-term use of angiotensin-converting enzyme inhibitors protects against bone loss in African-American elderly men.
Rianon N; Ambrose CG; Pervin H; Garcia M; Mama SK; Schwartz AV; Lee B; Harris T
Arch Osteoporos; 2017 Oct; 12(1):94. PubMed ID: 29080997
[TBL] [Abstract][Full Text] [Related]
7. beta-Blocker use, BMD, and fractures in the study of osteoporotic fractures.
Reid IR; Gamble GD; Grey AB; Black DM; Ensrud KE; Browner WS; Bauer DC
J Bone Miner Res; 2005 Apr; 20(4):613-8. PubMed ID: 15765180
[TBL] [Abstract][Full Text] [Related]
8. Changes in bone mineral density in men starting androgen deprivation therapy and the protective role of vitamin D.
Alibhai SM; Mohamedali HZ; Gulamhusein H; Panju AH; Breunis H; Timilshina N; Fleshner N; Krahn MD; Naglie G; Tannock IF; Tomlinson G; Warde P; Duff Canning S; Cheung AM
Osteoporos Int; 2013 Oct; 24(10):2571-9. PubMed ID: 23563932
[TBL] [Abstract][Full Text] [Related]
9. Association of Stimulant Medication Use With Bone Mass in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder.
Feuer AJ; Thai A; Demmer RT; Vogiatzi M
JAMA Pediatr; 2016 Dec; 170(12):e162804. PubMed ID: 27695823
[TBL] [Abstract][Full Text] [Related]
10. Association between beta-blocker use and fracture risk: the Dubbo Osteoporosis Epidemiology Study.
Yang S; Nguyen ND; Center JR; Eisman JA; Nguyen TV
Bone; 2011 Mar; 48(3):451-5. PubMed ID: 21047567
[TBL] [Abstract][Full Text] [Related]
11. Bone mineral density changes in hypercalciuretic osteoporotic men treated with thiazide diuretics.
Legroux-Gerot I; Catanzariti L; Marchandise X; Duquesnoy B; Cortet B
Joint Bone Spine; 2004 Jan; 71(1):51-5. PubMed ID: 14769521
[TBL] [Abstract][Full Text] [Related]
12. AI-related BMD variation in actual practice conditions: A prospective cohort study.
Rodríguez-Sanz M; Prieto-Alhambra D; Servitja S; Garcia-Giralt N; Garrigos L; Rodriguez-Morera J; Albanell J; Martínez-García M; González I; Diez-Perez A; Tusquets I; Nogués X
Endocr Relat Cancer; 2016 Apr; 23(4):303-12. PubMed ID: 26911377
[TBL] [Abstract][Full Text] [Related]
13. Angiotensin converting enzyme inhibitor use is associated with higher bone mineral density in elderly Chinese.
Lynn H; Kwok T; Wong SY; Woo J; Leung PC
Bone; 2006 Apr; 38(4):584-8. PubMed ID: 16257280
[TBL] [Abstract][Full Text] [Related]
14. Bone mineral density in rheumatoid arthritis patients 1 year after adalimumab therapy: arrest of bone loss.
Wijbrandts CA; Klaasen R; Dijkgraaf MG; Gerlag DM; van Eck-Smit BL; Tak PP
Ann Rheum Dis; 2009 Mar; 68(3):373-6. PubMed ID: 18408246
[TBL] [Abstract][Full Text] [Related]
15. Long-term effect of aromatase inhibitors on bone microarchitecture and macroarchitecture in non-osteoporotic postmenopausal women with breast cancer.
Hong AR; Kim JH; Lee KH; Kim TY; Im SA; Kim TY; Moon HG; Han WS; Noh DY; Kim SW; Shin CS
Osteoporos Int; 2017 Apr; 28(4):1413-1422. PubMed ID: 28083668
[TBL] [Abstract][Full Text] [Related]
16. The Benefit of Menopausal Hormone Therapy on Bone Density and Microarchitecture Persists After its Withdrawal.
Papadakis G; Hans D; Gonzalez-Rodriguez E; Vollenweider P; Waeber G; Marques-Vidal PM; Lamy O
J Clin Endocrinol Metab; 2016 Dec; 101(12):5004-5011. PubMed ID: 27854548
[TBL] [Abstract][Full Text] [Related]
17. Effect of selective serotonin reuptake inhibitors on bone mineral density: a systematic review and meta-analysis.
Zhou C; Fang L; Chen Y; Zhong J; Wang H; Xie P
Osteoporos Int; 2018 Jun; 29(6):1243-1251. PubMed ID: 29435621
[TBL] [Abstract][Full Text] [Related]
18. Prospective study of bone mineral density changes in aging men with or at risk for HIV infection.
Sharma A; Flom PL; Weedon J; Klein RS
AIDS; 2010 Sep; 24(15):2337-45. PubMed ID: 20683316
[TBL] [Abstract][Full Text] [Related]
19. Effects of ground and joint reaction force exercise on lumbar spine and femoral neck bone mineral density in postmenopausal women: a meta-analysis of randomized controlled trials.
Kelley GA; Kelley KS; Kohrt WM
BMC Musculoskelet Disord; 2012 Sep; 13():177. PubMed ID: 22992273
[TBL] [Abstract][Full Text] [Related]
20. Association between bone measures and use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers.
Holloway-Kew KL; Betson AG; Anderson KB; Gaston J; Kotowicz MA; Liao WH; Henneberg M; Pasco JA
Arch Osteoporos; 2021 Sep; 16(1):137. PubMed ID: 34536130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
